In addition to the Immunomedics transaction the company has announced nine additional oncology deals this year with an emphasis on immuno-oncology, including:

The $4.9bn acquisition of Forty Seven Inc.; (Also see "Gilead Calls Forty Seven Buyout Complementary To Kite, Other IO Efforts" - Scrip, 2 March, 2020.)
Kite’s multiple myeloma deal with Teneobio, Inc.; (Also see "Deal Watch: Alnylam/Dicerna Pact Addresses IP Questions Around Primary Hyperoxaluria Programs" - Scrip, 14 April, 2020.)
A deal worth $175m up front and $200m in equity with Arcus Biosciences; (Also see "Gilead Partnership With Arcus Brings PD-1, TIGIT Assets To Its IO Portfolio" - Scrip, 27 May, 2020.)
A $275m investment in a 49.9% stake in Pionyr Immunotherapeutics Inc.; (Also see "Gilead Wagers $275m On Pionyr’s Myeloid Tuners" - Scrip, 23 June, 2020.)
A 49.9% stake in Tizona Therapeutics, Inc. for $300m; (Also see "Gilead Gets Option To Tizona's Novel HLA-G Checkpoint, Further Bulking Up Immune Checkpoint Arsenal" - Scrip, 21 July, 2020.)
A $125m upfront payment and $25m investment in a series B round to expand an agreement with Tango Therapeutics, Inc.; (Also see "Gilead Decides On Bigger Dance Floor With Tango" - Scrip, 18 August, 2020.)
Kite’s natural killer cell collaboration with oNKo-innate Pty Ltd; (Also see "Deal Watch: Novartis Partners With TScan To Develop T-Cell Receptor-Targeted Therapies" - Scrip, 24 April, 2020.)
An IO deal with Jounce Therapeutics, Inc. for $120m up front; (Also see "Gilead Licenses Novel Immunotherapy From Jounce" - Scrip, 1 September, 2020.) and
Kite’s partnerships with HiFiBiO Therapeutics in AML. (Also see "Deal Watch: Kite Inks Novel AML Target Discovery Tie-Up With HiFiBiO" - Scrip, 4 September, 2020.)

Gilead Buys Pipeline-In-A-Product With $21bn Immunomedics Deal

Acquisition Gives The Big Biotech Its First Approved Solid Tumor Drug

More from Deals

More from Business